Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer

go back to reference Adjei AA (2004) Pharmacology and mechanism of action of pemetrexed. Clinical Lung Cancer 5(Suppl 2):S51–55CrossRefPubMed Adjei AA (2004) Pharmacology and mechanism of action of pemetrexed. Clinical Lung Cancer 5(Suppl 2):S51–55CrossRefPubMed

go back to reference Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, Ouafik LH, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier P-P, Lamy R, Beau-Faller M, Pujol J-L, Sabourin J-C, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria J-C, Zalcman G (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet 387(10026):1415–1426. https://doi.org/10.1016/S0140-6736(16)00004-0 CrossRef Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, Ouafik LH, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier P-P, Lamy R, Beau-Faller M, Pujol J-L, Sabourin J-C, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria J-C, Zalcman G (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet 387(10026):1415–1426. https://​doi.​org/​10.​1016/​S0140-6736(16)00004-0 CrossRef

go back to reference Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://​doi.​org/​10.​1056/​NEJMoa1507643 CrossRefPubMedPubMedCentral

go back to reference Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6(2):404–417. https://doi.org/10.1158/1535-7163.Mct-06-0343 CrossRefPubMed Chattopadhyay S, Moran RG, Goldman ID (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6(2):404–417. https://​doi.​org/​10.​1158/​1535-7163.​Mct-06-0343 CrossRefPubMed

go back to reference Chen K-C, Yang T-Y, Wu C-C, Cheng C-C, Hsu S-L, Hung H-W, Chen J-W, Chang G-C (2014) Pemetrexed induces s-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway. PLoS ONE 9(5):e97888. https://doi.org/10.1371/journal.pone.0097888 CrossRefPubMedPubMedCentral Chen K-C, Yang T-Y, Wu C-C, Cheng C-C, Hsu S-L, Hung H-W, Chen J-W, Chang G-C (2014) Pemetrexed induces s-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway. PLoS ONE 9(5):e97888. https://​doi.​org/​10.​1371/​journal.​pone.​0097888 CrossRefPubMedPubMedCentral

go back to reference Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM (2012) Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother (Hagerstown Md: 1997) 35(8):629–640. https://doi.org/10.1097/cji.0b013e31826c8a4f CrossRef Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM (2012) Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother (Hagerstown Md: 1997) 35(8):629–640. https://​doi.​org/​10.​1097/​cji.​0b013e31826c8a4f​ CrossRef

go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer (Oxford, Engl: 1990) 45(2):228–247CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer (Oxford, Engl: 1990) 45(2):228–247CrossRef

go back to reference Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3(5):436–443. https://doi.org/10.1158/2326-6066.Cir-15-0064 CrossRefPubMedPubMedCentral Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3(5):436–443. https://​doi.​org/​10.​1158/​2326-6066.​Cir-15-0064 CrossRefPubMedPubMedCentral

go back to reference Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28(6):690–714. https://doi.org/10.1016/j.ccell.2015.10.012 CrossRefPubMed Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28(6):690–714. https://​doi.​org/​10.​1016/​j.​ccell.​2015.​10.​012 CrossRefPubMed

go back to reference Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092. https://doi.org/10.1056/NEJMoa1801005 CrossRefPubMed Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092. https://​doi.​org/​10.​1056/​NEJMoa1801005 CrossRefPubMed

go back to reference Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33(18):2004–U2032. https://doi.org/10.1200/jco.2014.58.3708 CrossRefPubMedPubMedCentral Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33(18):2004–U2032. https://​doi.​org/​10.​1200/​jco.​2014.​58.​3708 CrossRefPubMedPubMedCentral

go back to reference Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (Lond Engl) 387(10027):1540–1550. https://doi.org/10.1016/s0140-6736(15)01281-7 CrossRef Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (Lond Engl) 387(10027):1540–1550. https://​doi.​org/​10.​1016/​s0140-6736(15)01281-7 CrossRef

go back to reference Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Inoue K, Mori K, Fujii H, Mano H, Odgerel T, Furukawa Y (2006) Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol Res 16(2):85–95CrossRefPubMed Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Inoue K, Mori K, Fujii H, Mano H, Odgerel T, Furukawa Y (2006) Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol Res 16(2):85–95CrossRefPubMed

go back to reference Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:9. https://doi.org/10.1038/ncomms10501 CrossRef Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:9. https://​doi.​org/​10.​1038/​ncomms10501 CrossRef

go back to reference Kuo WT, Tu DG, Chiu LY, Sheu GT, Wu MF (2017) High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase. Oncol Rep 38(5):2787–2795. https://doi.org/10.3892/or.2017.5951 CrossRefPubMedPubMedCentral Kuo WT, Tu DG, Chiu LY, Sheu GT, Wu MF (2017) High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase. Oncol Rep 38(5):2787–2795. https://​doi.​org/​10.​3892/​or.​2017.​5951 CrossRefPubMedPubMedCentral

go back to reference Lin EP-Y, Yang C-Y, Lin C-W, Huang B-T, Lai W-Y, Tseng Y-T, Yang P-C (2017) Priming PD-L1 expression by chemotherapeutic agents in non-small cell lung cancers. J Clin Oncol 35(15_suppl):e20087–e20087. https://doi.org/10.1200/jco.2017.35.15_suppl.e20087 CrossRef Lin EP-Y, Yang C-Y, Lin C-W, Huang B-T, Lai W-Y, Tseng Y-T, Yang P-C (2017) Priming PD-L1 expression by chemotherapeutic agents in non-small cell lung cancers. J Clin Oncol 35(15_suppl):e20087–e20087. https://​doi.​org/​10.​1200/​jco.​2017.​35.​15_​suppl.​e20087 CrossRef

go back to reference Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, Pampillo M, Rytelewski M, Vincent M, Min W, Zheng X, Koropatnick J (2015) IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells. PLoS ONE 10(11):e0143435. https://doi.org/10.1371/journal.pone.0143435 CrossRefPubMedPubMedCentral Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, Pampillo M, Rytelewski M, Vincent M, Min W, Zheng X, Koropatnick J (2015) IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells. PLoS ONE 10(11):e0143435. https://​doi.​org/​10.​1371/​journal.​pone.​0143435 CrossRefPubMedPubMedCentral

go back to reference Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. https://doi.org/10.1056/NEJMoa0810699 CrossRefPubMed Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. https://​doi.​org/​10.​1056/​NEJMoa0810699 CrossRefPubMed

go back to reference Park S, Kim HJ, Choi CM, Lee DH, Kim SW, Lee JS, Kim WS, Choi SH, Rho JK, Lee JC (2016) Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. BMC cancer 16:417. https://doi.org/10.1186/s12885-016-2457-0 CrossRefPubMedPubMedCentral Park S, Kim HJ, Choi CM, Lee DH, Kim SW, Lee JS, Kim WS, Choi SH, Rho JK, Lee JC (2016) Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. BMC cancer 16:417. https://​doi.​org/​10.​1186/​s12885-016-2457-0 CrossRefPubMedPubMedCentral

go back to reference Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31(23):2895. https://doi.org/10.1200/jco.2012.47.1102 CrossRefPubMed Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31(23):2895. https://​doi.​org/​10.​1200/​jco.​2012.​47.​1102 CrossRefPubMed

go back to reference Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ (2014) Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother CII 63(7):721–735. https://doi.org/10.1007/s00262-014-1549-4 CrossRefPubMed Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ (2014) Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother CII 63(7):721–735. https://​doi.​org/​10.​1007/​s00262-014-1549-4 CrossRefPubMed

go back to reference Putri DU, Feng P-H, Hsu Y-H, Lee K-Y, Jiang F-W, Kuo L-W, Chen Y-J, Han C-L (2018) Chemotherapy immunophenoprofiles in non-small-cell lung cancer by personalized membrane proteomics. Proteom Clin Appl 12(2):1700040. https://doi.org/10.1002/prca.201700040 CrossRef Putri DU, Feng P-H, Hsu Y-H, Lee K-Y, Jiang F-W, Kuo L-W, Chen Y-J, Han C-L (2018) Chemotherapy immunophenoprofiles in non-small-cell lung cancer by personalized membrane proteomics. Proteom Clin Appl 12(2):1700040. https://​doi.​org/​10.​1002/​prca.​201700040 CrossRef

go back to reference Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016a) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMed Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016a) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://​doi.​org/​10.​1056/​NEJMoa1606774 CrossRefPubMed

go back to reference Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016b) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMed Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016b) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://​doi.​org/​10.​1056/​NEJMoa1606774 CrossRefPubMed

go back to reference Restifo NP, Smyth MJ, Snyder A (2016) Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16:121. https://doi.org/10.1038/nrc.2016.2 CrossRefPubMedPubMedCentral Restifo NP, Smyth MJ, Snyder A (2016) Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16:121. https://​doi.​org/​10.​1038/​nrc.​2016.​2 CrossRefPubMedPubMedCentral

go back to reference Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. https://doi.org/10.1016/S1470-2045(11)70393-X CrossRefPubMed Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. https://​doi.​org/​10.​1016/​S1470-2045(11)70393-X CrossRefPubMed

go back to reference Tièche CC, Peng R-W, Dorn P, Froment L, Schmid RA, Marti TM (2016) Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. BMC Cancer 16:125–125. https://doi.org/10.1186/s12885-016-2117-4 CrossRefPubMedPubMedCentral Tièche CC, Peng R-W, Dorn P, Froment L, Schmid RA, Marti TM (2016) Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. BMC Cancer 16:125–125. https://​doi.​org/​10.​1186/​s12885-016-2117-4 CrossRefPubMedPubMedCentral

go back to reference Wilson PM, Danenberg PV, Johnston PG, Lenz H-J, Ladner RD (2014) Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 11:282. https://doi.org/10.1038/nrclinonc.2014.51 CrossRefPubMed Wilson PM, Danenberg PV, Johnston PG, Lenz H-J, Ladner RD (2014) Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 11:282. https://​doi.​org/​10.​1038/​nrclinonc.​2014.​51 CrossRefPubMed

go back to reference Yoshida T, Okamoto T, Yano T, Takada K, Kohno M, Suda K, Takenoyama M, Oda Y, Maehara Y (2016) Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer. Anticancer Res 36(12):6319–6326. https://doi.org/10.21873/anticanres.11228 CrossRefPubMed Yoshida T, Okamoto T, Yano T, Takada K, Kohno M, Suda K, Takenoyama M, Oda Y, Maehara Y (2016) Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer. Anticancer Res 36(12):6319–6326. https://​doi.​org/​10.​21873/​anticanres.​11228 CrossRefPubMed

go back to reference Zhang P, Bao Z, Xu L, Zhou J, Lu G, Yao Y, Liu R, Gao Q, Shen Y, Zhou J (2017) PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget 8(39):66293–66304. https://doi.org/10.18632/oncotarget.19973 CrossRefPubMedPubMedCentral Zhang P, Bao Z, Xu L, Zhou J, Lu G, Yao Y, Liu R, Gao Q, Shen Y, Zhou J (2017) PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. Oncotarget 8(39):66293–66304. https://​doi.​org/​10.​18632/​oncotarget.​19973 CrossRefPubMedPubMedCentral